newsfilter
← Latest News
Business Wire·

Forest Laboratories and Almirall Decide to Delay NDA Filing for Aclidinium/formoterol Combination

NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM:MC) today announced that they will delay the planned Q4 2013 submission of a New Drug Application (NDA) for the combination of aclidinium bromide, a long acting muscarinic antagonist and formoterol fumarate, a long acting beta agonist, for the indication of Chronic Obstructive Pulmonary Disease (COPD). This decision was based on comments provided by the FDA at a recent pre-NDA meeting.